Mood and emotional wellbeing: Hormonal interventions

[ show contents ]
View the PDF
Print the PDF

Background
Grading of Clinical Practice Recommendations
Clinical Practice Recommendations and Practice Points
Summary of Evidence - Methodology
Summary of Evidence - Introduction
Summary of Evidence - Vasomotor symptoms
Summary of Evidence - Sleep disturbance
Summary of Evidence - Vulvovaginal symptoms and sexual function
Summary of Evidence - Depression and anxiety
Summary of Evidence - Mood and emotional wellbeing
- Mood and emotional wellbeing: Pharmacological interventions
- Mood and emotional wellbeing: Hormonal interventions
- Mood and emotional wellbeing: Psychological and physical interventions
Summary of Evidence - Mental health
Summary of Evidence - Global quality of life
Summary of Evidence - Breast cancer recurrence
Strengths and Weaknesses of the Evidence
Unanswered Questions Regarding Treatments of Interest
International Guidelines
Ongoing and Additional Trials of Interest
Drug Contraindications and Side Effects
Evidence Matrix
References
Acknowledgements
Additional Information
Appendix 1: Grading Methodology
Appendix 2: Evidence Summaries
Appendix 3: Recommendation Grading Forms

Menopause hormone therapy

One RCT (with a low risk of bias) in women after breast cancer found a statistically significant improvement in depressed mood for tibolone (2.5mg/d for a mean of 2.5 years) compared with placebo.³⁵

Other hormone therapies

In a population of peri- and postmenopausal women, two RCTs in a systematic review found that the addition of testosterone to menopause hormone therapy had no effect on overall wellbeing.⁴⁴ In a population of postmenopausal women, nine RCTs found that testosterone reduced personal distress, but other RCTs in the systematic review found that testosterone had no effect on anxiety (four RCTs) or depressed mood (five RCTs).⁸⁷

Mood and emotional wellbeing: Hormonal interventions